gmp
gmp

Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Novartis Pharmaceuticals Corporation

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWITZERLAND Switzerland

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Food & Nutrition Conference 2020

              Participation Not Confirmed

              Update your events

              Next-Generation Wet AMD Therapy Beovu®, Now Available in Canada, Receives Positive Recommendation from CADTH Drug Expert Committee¹

              Contact the Supplier

              Lead Product(s): Brolucizumab

              Therapeutic Area: Ophthalmology Product Name: Beovu

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 05, 2020

              Details:

              Beovu® is an anti-VEGF treatment that offers patients extended treatment period between doses following initial dose with no compromise in efficacy.

              Novartis Pharmaceuticals Corporation

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWITZERLAND Switzerland

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Food & Nutrition Conference 2020

              Participation Not Confirmed

              Update your events

              European Medicines Agency Approves Safety Label Update for Novartis Beovu®

              Contact the Supplier

              Lead Product(s): Brolucizumab

              Therapeutic Area: Ophthalmology Product Name: Beovu

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 14, 2020

              Details:

              CHMP has approved an update to the Beovu® (brolucizumab) Summary of Product Characteristics (SmPC) to include additional information regarding retinal vasculitis and retinal vascular occlusion.

              PharmaCompass__DigitalAd